Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Humbert

Showing results (91-100 of 190) with videos related to

Pageof 19
Sort By:
Reviews of Infectious Diseases|September 1, 1982
The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal functionR M Ings, J P Fillastre, M Godin, et al.
Clinical Pharmacology and Therapeutics|November 1, 1979
Sulfinpyrazone kinetics after intravenous and oral administrationJ B Lecaillon, C Souppart, J P Schoeller, et al.
Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association|January 1, 1973
Pharmocodynamics of lividomycin in renal failureJ P Fillastre, G Humbert, M F Daufresne, et al.
Journal of Dairy Science|June 1, 1995
Proteolysis in samples of quarter milk with varying somatic cell counts. 2. Component PP3 and beta-casein-1P (f29-105 and f29-107) of the proteose-peptone fractionY Le Roux, J M Girardet, G Humbert, et al.
Nephrologie|January 1, 1982
[Pharmacokinetics of cefotaxime and metabolites in uremic patients (author's transl)]J P Fillastre, R M Ings, A Leroy, et al.
La Presse Medicale|October 30, 1971
[Spontaneous retroperitoneal hematoma during anticoagulant treatment]J M Droy, D Dubois, G Humbert, et al.
Current Therapeutic Research, Clinical and Experimental|March 1, 1974
Study of the serum half life of lividomycin in uraemic patientsG Humbert, J P Fillastre, M F Daufresne, et al.
Presse Medicale (Paris, France : 1983)|April 20, 1996
[Bilateral C8 meningoradiculitis in infectious mononucleosis]P Auzou, D Hannequin, C Ozsancak, et al.
Antimicrobial Agents and Chemotherapy|December 1, 1992
Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairmentA Leroy, J P Fillastre, F Borsa-Lebas, et al.
La Nouvelle Presse Medicale|February 9, 1980
[Antibiotic audit]J Acar, M Armengaud, J Drucker, et al.
Pageof 19

Showing results (91-100 of 190) with videos related to

Sort By:
Pageof 19
Reviews of Infectious Diseases|September 1, 1982
The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal functionR M Ings, J P Fillastre, M Godin, et al.
Clinical Pharmacology and Therapeutics|November 1, 1979
Sulfinpyrazone kinetics after intravenous and oral administrationJ B Lecaillon, C Souppart, J P Schoeller, et al.
Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association|January 1, 1973
Pharmocodynamics of lividomycin in renal failureJ P Fillastre, G Humbert, M F Daufresne, et al.
Journal of Dairy Science|June 1, 1995
Proteolysis in samples of quarter milk with varying somatic cell counts. 2. Component PP3 and beta-casein-1P (f29-105 and f29-107) of the proteose-peptone fractionY Le Roux, J M Girardet, G Humbert, et al.
Nephrologie|January 1, 1982
[Pharmacokinetics of cefotaxime and metabolites in uremic patients (author's transl)]J P Fillastre, R M Ings, A Leroy, et al.
La Presse Medicale|October 30, 1971
[Spontaneous retroperitoneal hematoma during anticoagulant treatment]J M Droy, D Dubois, G Humbert, et al.
Current Therapeutic Research, Clinical and Experimental|March 1, 1974
Study of the serum half life of lividomycin in uraemic patientsG Humbert, J P Fillastre, M F Daufresne, et al.
Presse Medicale (Paris, France : 1983)|April 20, 1996
[Bilateral C8 meningoradiculitis in infectious mononucleosis]P Auzou, D Hannequin, C Ozsancak, et al.
Antimicrobial Agents and Chemotherapy|December 1, 1992
Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairmentA Leroy, J P Fillastre, F Borsa-Lebas, et al.
La Nouvelle Presse Medicale|February 9, 1980
[Antibiotic audit]J Acar, M Armengaud, J Drucker, et al.
Pageof 19